IL6 and myeloid sarcoma: In multivariable MR analyses with IL-6 signaling data from the CHARGE consortium, the effect of IL-6 signaling on MS remained after adjusting for BMI (OR = 1.36, 95% CI = 1.11-1.68, p = 0.003), with smaller effect estimate and confidence intervals after adjustment (Figure 3).